Interim report January - September 2026



Accelerating growth and stronger earnings

July – September 2026


- **Net sales** totaled SEK 36,872 (27,532) thousand, representing a growth of 34%, which also corresponds to growth adjusted for currency effects.
- **Operating profit before depreciation and amortization** (EBITDA) totaled SEK 10,289 (6,878) thousand.
- **Earnings per share** totaled SEK 0.06 (0.12). Prior year includes a gain on the disposal of an associate equivalent to SEK 0.10 per share.
- **Cash flow from operating activities** was SEK 14,580 (10,875) thousand.

January – September 2026


- On 1 June 2026, Genovis AB acquired 100% of the shares in KPL ApS, a Danish life science tools company with a proprietary portfolio of precision enzymes (proteases), including both commercialized products and products under development, for mass spectrometry-based protein analysis in academic research, diagnostics, and drug development.
- **Net sales** totaled SEK 104,694 (88,694) thousand, representing growth of 18%, corresponding to 24% when adjusted for currency effects.
- **Operating profit before depreciation and amortization (**EBITDA**)** totaled SEK 26,640 (21,820) thousand and was affected by transaction costs of SEK 3,492 thousand related to the acquisition of KPL ApS in the second quarter. Adjusted for these costs, EBITDA amounted to SEK 30,132 thousand.
- **Earnings per share** totaled SEK 0.15 (0.25) and were affected by transaction costs related to the acquisition of KPL ApS. Adjusted for these costs, earnings per share amounted to SEK 0.20. Prior year includes a gain on the disposal of an associate equivalent to SEK 0.10 per share.
- **Cash flow from operating activities** was SEK 38,994 (16,126) thousand.

Core business net sales (reagents), rolling 12 months

Enzyme products and services, excluding licence revenue and bioprocessing



Net Sales by quarter 2023 – 2026



Comments from Fredrik Olsson, Chief Executive Officer



The third quarter was characterised by strong growth, with our broader business increasingly reflected in our results. Sales grew by a third, profitability improved and all parts of the business contributed. Following a second quarter marked by acquisitions and non-recurring expenses, the third quarter demonstrated more clearly the strength of the platform we are bulding.

Net sales amounted to SEK 36,872 thousand (27,532), an increase of 34 percent compared with the same period of the prior year. Growth was broad-based, driven by both our established Analytics business and a very strong performance in Genomics.

Profitability improved significantly during the quarter. EBITDA amounted to SEK 10,289 thousand (6,878), an increase of 50 percent, while operating profit (EBIT) rose by just over 70 percent to SEK 5,776 thousand (3,374). The improvement in earnings is particularly encouraging given our larger organization, increased expenses following the acquisitions and certain non-recurring expenses.

Our business is built on three complementary areas – Analytics, Genomics and Proteomics – all of which contributed to the quarter's performance.

The established Analytics business continued to perform well during the quarter. Excluding services, product sales grew by approximately 18 percent, supported by healthy demand across several customer segments. Performance was particularly strong in North America, while Europe was slightly weaker than in the prior year, which we believe primarily reflects project-related fluctuations at major pharmaceutical companies. Asia continued to grow.

The services business remained weak during the quarter. This business is project-based and concentrated among a small number of customers, resulting in uneven revenue. However, we are now seeing increased activity in enquiries and requests for quotations at the start of the fourth quarter, which is an encouraging sign.

Within Analytics, we continue to develop the commercial opportunities for our ADC technologies. During the quarter, we strengthened our relationships with several CROs and CDMOs, which play an important role as drug development projects progress towards clinical development and manufacturing. In parallel, discussions continue with customers evaluating our technologies for their clinical programmes. Development remains at an early stage, but our progress strengthens the prospects for establishing new revenue streams from licensing and commercial manufacturing over time.

Genomics continued to perform exceptionally well and once again delivered its strongest quarter to date, with sales more than doubling compared with the previous quarter. The largest single driver was substantial OEM sales to a kit manufacturer that incorporates SEQURNA technology into its products. At the same time, SEQguard™ continued to grow, with broad demand from leading academic institutions, largely through our collaboration with Plasmidsaurus. In September, SEQguard achieved its highest monthly sales volume to date.

During the quarter, Genomics reached an important milestone, with rolling 12-month sales well above SEK 10 million. OEM sales can vary considerably between quarters, but this performance demonstrates how the technology can drive growth through both major industrial partnerships and an

expanding academic customer base. Overall, Genomics has performed ahead of our expectations and is increasingly establishing itself as an important contributor to Genovis' future growth.

In our Proteomics business the integration of KPL made significant progress during the quarter. Within a short period, we successfully transferred and established production at Genovis while broadening our commercial offering in Proteomics. Towards the end of the quarter, we launched TrypsINATOR™ and TrypsINATOR™ Mix, two products added through the acquisition, and received the first orders during the quarter. At the HUPO congress in late September, we also introduced the new enzyme KRysin™, which attracted considerable interest. Together, these products strengthen our offering in mass spectrometry-based protein analysis and create new opportunities for long-term growth in Proteomics.

Our own innovation platform also continues to deliver. AlligBAITOR™, launched at the end of the second quarter, has been well received by the market and has shown promising sales development since launch.

Overall, the third quarter saw our broader business begin to demonstrate its strength, with strong growth, improved profitability and clear progress in both Genomics and Proteomics. We enter the final quarter of the year with a broader product portfolio and a more diversified business than ever before.

Finally, I would like to extend a special thank you to all Genovis employees for your commitment and contributions during the quarter. Completing the transfer of production from KPL within a single quarter required considerable effort, flexibility and close collaboration across the organization. This is an achievement of which I am particularly proud, and one that demonstrates the strength of our organization. It is also encouraging to see how our colleagues from KPL have become an integral part of Genovis. Alongside the integration, the rest of the business has continued to perform strongly. Through our shared commitment and collaboration, we can continue to develop Genovis and create long-term value for our customers, employees and shareholders.

The Genovis Group

Genovis will apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future.

Genovis develops and markets innovative enzyme technologies for research, development, and production within life science and biopharma.

The company's technologies are currently used in three complementary areas:

- Protein analysis and drug development
- Genomics
- Proteomics

Through continuous product development and strategic acquisitions, Genovis is progressively broadening its offering and creating multiple long-term growth opportunities.

The product portfolio today comprises a broad range of enzyme-based products and services for protein analysis, enzyme-based conjugation, and analytical services. The acquisition of SEQURNA AB in 2025 established a new business area within Genomics, based on a unique RNase inhibitor technology for RNA analysis and applications including mRNA manufacturing. During 2026, the Group was further expanded through the acquisition of KPL ApS, which established Genovis within Proteomics with a complementary product portfolio of enzymes for proteomics.

The parent company in Kävlinge is responsible for research and development, production, and sales and marketing in markets outside North America. The subsidiary Genovis Inc. is responsible for sales and marketing in North America, while sales in Asia are conducted mainly through local distributors. Genovis also has its own market presence through product specialists in Denmark, Germany, France, Spain, Italy, and China.



Genovis' business model is based on long-term, sustainable value creation through innovation, close customer relationships, and strategic broadening of the technology platform. The company's strategy is built on three main priorities:

- Continuing to launch new, unique products and services, thereby broadening the customer offering to support continued strong growth.
- Working purposefully to ensure that customers use Genovis products throughout the entire process, up to the release and approval of new biological drugs.
- Broadening the customer offering through inorganic growth initiatives such as in-licensing and the acquisition of technologies or companies.

An increasing number of customers are now using Genovis' technologies further along the development process, from early research to development, production, and quality control of biological drugs. This strengthens the company's long-term customer relationships and creates favorable conditions for continued growth.

Financial overview

The Group's financial performance in summary

	jul-sep		jan-sep		full year
(SEK 000s)	2026	2025	2026	2025	2025
Net Sales	36,872	27,532	104,694	88,694	128,946
Gross margin %[1]	88.7%	89.5%	88.3%	89.5%	89.3%
Operating profit before depreciation and amortization (EBITDA)	10,289	6,878	26,640	21,820	33,558
Operating margin before depreciation and amortization %[2]	27.9%	25.0%	25.4%	24.6%	26.0%
Operating profit (EBIT)	5,776	3,374	14,374	13,221	21,283
Operating margin %[3]	15.7%	12.3%	13.7%	14.9%	16.5%
Profit margin %[4]	11.3%	29.2%	9.3%	18.7%	18.2%
Earnings per share[5] (SEK)	0.06	0.12	0.15	0.25	0.36
Cash flow from operating activities	14,580	10,875	38,994	16,126	32,022


[1] Gross margin is calculated by dividing the sum of net sales, change in inventory of finished goods and raw materials and consumables by net sales.
[2] Operating margin before depreciation and amortization is calculated by dividing operating profit before depreciation and amortization (EBITDA) by net sales.
[3] Operating margin is calculated by dividing operating profit (EBIT) by net sales.
[4] Profit margin is calculated by dividing profit for the period by net sales.
[5] Earnings per share are calculated by dividing profit by the weighted average number of shares during the year. There is no dilutive effect.

Revenue

Consolidated net sales for the third quarter totaled SEK 36,872 (27,532) thousand a growth in sales of 34%, which also corresponds to growth adjusted for currency effects. The change in inventory, finished goods, amounted to SEK -654 (-399) thousand. Capitalized work for own account amounted to SEK 593 (206) thousand. Other operating income totaled SEK 3,131 (1,446) thousand. Other operating income for the quarter mainly relates to foreign exchange gains (see also foreign exchange losses in other operating expenses under the expenses section below). These gains have primarily arisen from the translation of the company's assets and liabilities denominated in foreign currencies into SEK, with the largest impact related to USD.

Consolidated net sales for the first nine months totaled SEK 104,694 (88,694) thousand, a growth of 18%, 24% when adjusted for currency effects. Net sales include approximately SEK 1 million in upfront license revenue related to the EndoS2 enzyme technology recognized in the first quarter. The change in inventory, finished goods, amounted to SEK -62 (345) thousand. Capitalized work for own account amounted to SEK 1,266 (700) thousand. Other operating income amounted to SEK 9,369 (2,552) thousand. Other operating income mainly relates to foreign exchange gains (see also foreign exchange losses in other operating expenses under the expenses section below). These gains have primarily arisen from the translation of the company's assets and liabilities denominated in foreign currencies into SEK, with the largest impact related to USD.

Sales revenue, 12-month rolling (2024 – 2026)



Expenses

Consolidated expenses for the third quarter totaled SEK 34,166 (25,411) thousand. Expenses are allocated as follows: raw materials and consumables SEK 3,516 (2,482) thousand, personnel expense SEK 14,854 (10,260) thousand, other external expenses SEK 9,627 (6,344) thousand and other operating expenses SEK 1,656 (2,821) thousand. Personnel expenses increased compared with the previous year, primarily due to salary increases, new hires, additional employees acquired through the acquisition of KPL ApS and non-recurring personnel expenses. Other external expenses increased primarily due to the ERP system implementation and R&D-related expenses. Other operating expenses consist of exchange rate losses (see also foreign exchange gains in other operating income under the revenue section above). The exchange rate losses mainly arose from the revaluation of the company's assets and liabilities denominated in foreign currencies to SEK, with the largest impact related to the USD. Prior year other operating expense contained transaction cost related to the acquisition of Sequrna AB amounting to SEK 1,287 thousand. Depreciation for the quarter amounted to SEK 4,513 (3,504) thousand. The increase in depreciation is primarily attributable to amortization of SEK 675 thousand on identified assets, such as development platform, in connection with the acquisitions of KPL ApS in June 2026, as well as depreciation of right-of-use assets for premises in Sequrna AB.

For the first nine months, expenses totaled SEK 100,893 (79,070) thousand. Expenses are allocated as follows: raw materials and consumables SEK 12,217 (9,691) thousand, personnel costs SEK 41,403 (32,124) thousand, other external expenses SEK 25,246 (20,857) thousand, other operating expenses SEK 9,761 (7,799) thousand. The increase in personnel expenses is due to salary increases, new hires, additional employees following the acquisition of Sequrna AB and KPL ApS and non-recurring personnel expenses. Other external expenses increased primarily due to the ERP system implementation and R&D expenses. Other operating expenses consist of transaction costs related to the acquisition of KPL amounting to SEK 3,492 thousand, as well as of exchange rate losses. The losses mainly arose from the revaluation of the company's assets and liabilities denominated in foreign currencies into Swedish kronor, with the largest impact related to the USD. Prior year other operating expense contained transaction cost related to the acquisition of Sequrna AB amounting to SEK 1,287 thousand. Depreciation and amortization for the first nine months totaled SEK 12,266 (8,599) thousand. The increase in depreciation is due to depreciation of a license recognized following the license agreement with Thermo Fisher in 2025, depreciation of identified intangible assets, such as customer relationships and the development platform, arising from the


acquisitions of Sequrna AB in 2025 and KPL ApS in 2026, as well as depreciation of right-of-use assets for premises in Sequrna.

Operating profit before depreciation and amortization (EBITDA)

For the third quarter, EBITDA totaled SEK 10,289 (6,878) thousand. EBITDA was positively impacted by SEK 838 (-89) thousand due to exchange rate variances, primarily as a result of a stronger USD relative to SEK during the quarter. Prior year other operating expense contained transaction cost related to the acquisition of Sequrna AB amounting to SEK 1,287 thousand.

For the first nine months, EBITDA totaled SEK 26,640 (21,820) thousand. Adjusted EBITDA, excluding items affecting comparability, amounted to SEK 30,132 thousand, adjusted for transaction costs of SEK -3,492 thousand related to the acquisition of KPL ApS. Prior year other operating expense contained transaction cost related to the acquisition of Sequrna AB amounting to SEK 1,287 thousand. EBITDA was positively impacted by SEK 2,302 (-4,131) thousand due to exchange rate variances, primarily as a result of a stronger USD relative to SEK.

Operating profit/loss before depreciation and amortization (EBITDA) per quarter



Operating profit (EBIT)

For the third quarter, EBIT totaled SEK 5,776 (3,374) thousand. Depreciation and amortization increased by SEK 1,009 thousand compared with the previous year, primarily due to the acquisition of intangible assets, which had a negative impact on EBIT. Prior year other operating expense contained transaction cost related to the acquisition of Sequrna AB amounting to SEK 1,287 thousand.

For the first nine months, EBIT totaled SEK 14,374 (13,221) thousand. Adjusted EBIT, excluding items affecting comparability, amounted to SEK 17,866 thousand, adjusted for transaction costs of SEK -3,492 thousand related to the acquisition of KPL ApS. Prior year other operating expense contained transaction cost related to the acquisition of Sequrna AB amounting to SEK 1,287 thousand. Depreciation and amortization increased by SEK 3,667 thousand compared with the previous year, primarily due to the acquisition of intangible assets, which had a negative impact on EBIT.

Taxes

The Group has a deferred tax asset of SEK 11,202 (8,183) thousand and relates to deferred tax on intra-group profit on inventories and right-of-use assets.

Deferred tax liability for the Group totals SEK 10,993 (5,922) thousand. The liability related to deferred tax on surplus values from the acquisition of Sequrna AB and KPL ApS.

Profit and comprehensive income for the period

Profit after tax for the third quarter was SEK 4,163 (8,026) thousand. The prior year includes a gain of SEK 6,293 thousand on the disposal of the associate Sequrna AB, arising in connection with the acquisition of full ownership of the company. Earnings per share for the third quarter, based on a weighted average of the number of outstanding shares, totaled SEK 0.06 (0.12).

Comprehensive income for the third quarter totaled SEK 5,938 (8,870) thousand.

Profit after tax for the first nine months totaled SEK 9,730 (16,598) thousand. The prior year includes a gain of SEK 6,293 thousand on the disposal of the associate Sequrna AB, arising in connection with the acquisition of full ownership of the company. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK 0.15 (0.25). Adjusted earnings per share, excluding items affecting comparability, amounted to SEK 0.20, adjusted for transaction costs related to the acquisition of KPL ApS.

Comprehensive income for the first nine months was SEK 14,581 (19,714) thousand.

Acquisition of KPL ApS

Genovis AB acquired 100% of the shares in KPL ApS on June 1, 2026, a Danish life science tools company with a proprietary portfolio of precision enzymes (proteases). The purchase price for the acquisition amounted to SEK 49,666 thousand, of which SEK 16,020 thousand was paid in cash, SEK 28,051 thousand was settled through newly issued shares to KPL’s founders, and the remaining portion is a contingent consideration. The contingent consideration is linked to the future commercial performance of KPL's products during the period from 1 June 2026 to 31 March 2029 (the "Earn-out Period"). The contingent consideration is conditional upon KPL's products achieving cumulative sales of SEK 24.4 million during the Earn-out Period and, accordingly, cannot be determined at the acquisition date. Subject to the condition being met, the contingent consideration will be paid in early 2030. At the acquisition date, the contingent consideration was measured at SEK 5,595 thousand. Transaction costs of SEK 3,492 thousand were recognized in the income statement as other operating expenses. The acquisition of KPL comprised net assets with a carrying amount of SEK 1,118 thousand and identified surplus values related to the development platform, including deferred tax, of SEK 21,455 thousand. Goodwill amounted to SEK 27,093 thousand and mainly represents future economic benefits in the form of expected synergies in sales and marketing functions, distribution channels, and geographical presence, as well as the collective expertise of the personnel in the acquired company.

KPL ApS reported net sales of DKK 969 thousand and profit for the year of DKK 14 thousand for the 2025/2026 financial year.

Acquisition Analysis

Acquired Net Assets (SEK 000s)	
Development platform	27,022
Inventories, trade receivables and other receivables	820
Cash and cash equivalents	460
Trade payables and other liabilities	-162
Deferred tax liability	-5,567
Total acquired net assets	**22,573**
Goodwill	27,093
Total purchase consideration	**49,666**
Allocation purchase consideration:	
Cash	16,020
Share issue in kind (newly issued shares to founders of KPL)	28,051
Contingent consideration	5,595

The acquisition analysis is subject to final adjustments no later than one year from the acquisition date.

Cash Flow Effect (SEK 000s)	
Transaction costs related to acquisition	-3,492
Operating activities	**-3,492**
Total purchase consideration	-49,666
Cash and cash equivalents in the acquired company	460
Investing activities	**-49,206**
Unpaid purchase consideration (contingent consideration)	5,595
Share issue in kind in connection with acquisition, net	27,833
Financing activities	**33,428**
Total cash flow effect, Group	**-19,270**

Investments

The Group's net capital expenditure for the third quarter totaled SEK 7,155 (42,139) thousand. The prior year includes SEK 40,979 thousand attributable to the purchase consideration for the acquisition of Sequrna AB. SEK 6,032 (132) thousand is attributable to property, plant, and equipment. SEK 1,122 (1,028) thousand is attributable to investments in intangible assets, of which SEK 593 (206) thousand relates to capitalized work for own account for new product development and the remainder refers to investments in patents.

For the first nine months, net capital expenditure totaled SEK 60,342 (52,037) thousand, of which SEK 49,206 thousand is attributable to the purchase consideration for the acquisition of KPL ApS. The prior year includes SEK 40,979 thousand attributable to the purchase consideration for the acquisition of Sequrna AB. SEK 7,852 (295) thousand is attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 3,284 (10,763) thousand relates to investments in intangible assets, of which SEK 1,266 (700) thousand relates to capitalized work for own account for new product development.

Cash flow and financial position

The total shareholders' equity for the Group was SEK 313,938 (263,534) thousand after taking the profit for the period into account. Equity per share based on the weighted average of the number of outstanding shares (basic and diluted) at the end of the period was SEK 4.71 (4.01). The Group's equity ratio at the end of the period was 71 (72) %.

Consolidated cash flow for the third quarter totaled SEK 5,821 (-14,101) thousand. Adjusted cash flow for the prior year, excluding the acquisition of the remaining 75% stake in Sequrna AB and the related share issue, amounted to SEK 12,317 thousand. Cash flow from financing activities amounted to SEK -1,604 thousand (17,163). The prior year includes proceeds from a share issue to finance the acquisition of Sequrna.

For the first nine months, consolidated cash flow was SEK -180 (-14,554) thousand. Adjusted cash flow, excluding the acquisition of KPL ApS and the related share issue, amounted to SEK 19,090 thousand. Adjusted cash flow for the prior year, excluding the acquisition of the remaining 75% stake in Sequrna AB and the related share issue, amounted to SEK 11,864 thousand. Cash flow from financing activities, including the share issue totaled SEK 21,168 (21,357) thousand.

Consolidated cash and cash equivalents at the end of the period amounted to SEK 163,012 (154,888) thousand. Taking expected revenue into account, the Board believes that the existing working capital is sufficient to run the Company over the next twelve months.

Only the Group has interest-bearing liabilities; they relate in their entirety to the present value of estimated future lease payments, which also include rent for premises.

Noncurrent lease liabilities maturing between 1-15 years totaled SEK 62,520 (71,492) thousand at the end of the period. Current lease liabilities maturing within 1 year totaled SEK 7,902 (1,573) thousand at the end of the period.

Employees

On September 30, 2026, the Group employed 43 (36) people. The Parent Company in Kävlinge employs 34 (30) people, in the subsidiary Sequrna AB, 3 (3) people are employed, in the subsidiary KPL ApS, 2 (0) people are employed and 4 (3) people work for the subsidiary Genovis Inc. in the US.

Share capital and the share

The share capital at the end of the quarter was SEK 16,864,595 and the total number of shares was 67,458,379 with a par value of SEK 0.25. As part of the acquisition of KPL ApS, a new share issue comprising 1,395,587 shares at a subscription price of SEK 20.10 per share was completed on June 1. The share issue increased the share capital by SEK 348,897 and increased equity by a net amount of SEK 27,833,364 after deduction of issue costs amounting to SEK 217,935.

Genovis shares are traded on Nasdaq First North Growth Market under the ticker symbol GENO. First North is Nasdaq's European emerging market intended for growth companies.

Certified adviser

The Company's Certified Adviser is DNB Carnegie Investment Bank AB

Parent Company

Net sales and operating income in the Parent Company are attributable to the primary and only business area: sales of products and/or research-based innovations.

Revenue

Revenue for the third quarter, including changes in inventories of finished goods and capitalized work for own account, totaled SEK 29,328 (21,126) thousand of which SEK 27,452 (19,600) thousand attributable to sales, SEK -918 (-28) thousand relating to a change in inventory of finished goods, SEK 378 (133) thousand arising from capitalized work for own account and SEK 2,416 (1,421) thousand in other operating income. For the first nine months, revenue totaled SEK 96,609 (79,034) thousand, including SEK 86,659 (75,576) thousand attributable to sales, SEK 418 (333) thousand relating to change in inventory, finished goods, SEK 1,044 (627) thousand arising from capitalized work for own account and SEK 8,488 (2,498) thousand attributable to other revenue. Other revenue mainly relates to foreign exchange gains.

Expenses

The Parent Company’s expenses for the third quarter totaled SEK 24,174 (18,704) thousand. For the first nine months, expenses totaled SEK 75,065 (61,913) thousand.

Performance

The profit for the third quarter was SEK 4,507 (2,954) thousand while profit for the first nine months was SEK 18,351 (17,473) thousand.

Investments

Net capital expenditure for the third quarter totaled SEK 7,155 (55,601) thousand of which SEK 6,032 (77) thousand is attributable to property, plant, and equipment. SEK 1,123 (956) thousand is attributable to investments in intangible assets of which SEK 378 (133) thousand relates to capitalized work for own account for new product development and the remainder refers to investments in patents and licenses. The previous year includes 54,568 attributable to the purchase consideration for the acquisition of the remaining 75% ownership interest in Sequrna AB. For the first nine months, net capital expenditure totaled SEK 63,907 (65,499) thousand, of which SEK 53,158 thousand is attributable to the purchase consideration for the acquisition of KPL ApS and SEK 7,687 (240) thousand attributable to property, plant, and equipment. SEK 3,062 (10,691) thousand is attributable to investments in intangible assets of which SEK 1,044 (627) thousand relates to capitalized work for own account for new product development and the remainder refers to investments in patents and licenses. The previous year includes 54,568 attributable to the purchase consideration for the acquisition of the remaining 75% ownership interest in Sequrna AB.

Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales and distribution of SmartEnzymes™ in the North American market.

Subsidiary Sequrna AB

The subsidiary Sequrna AB develops and markets next-generation RNase inhibitors, making RNA sequencing workflows more accessible, affordable and sustainable. Genovis owns 100% of Sequrna AB as of July 1, 2025.

Subsidiary KPL ApS

The subsidiary KPL ApS is a life science tools company that develops and markets sequencing-grade recombinant proteases for bottom-up proteomics workflows — Lys-C, Arg-C Zero™, Trypsin RMS, and Trypsin/Lys premium mix. The company's products are used in mass spectrometry-based protein analysis within biopharmaceutical research and development, quality control, and academic research. Genovis has owned 100% of KPL ApS since June 1, 2026.

Other information

Events after the end of the period
No significant events were reported after the end of the period.

Related party transactions
Genovis' board member and principal owner Mikael Lönn, who holds a 13.34% stake in Genovis, owns 15.27% of the shares in Redeye AB, for which Mikael Lönn is also a board member. Genovis purchased services from Redeye AB for a total of SEK 5 thousand during the first nine months.

Outlook
Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With most development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales in 2026. Even if external geopolitical factors and macroeconomic turmoil continue to represent an element of uncertainty, our current assessment is that our business opportunities and operational capacity are good.

Risk Factors
Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks, please refer to pages 55-56 in Genovis' 2025 Annual Report.

Auditor's review
This report has not been reviewed by the Company's auditor.

Financial calendar

Year-End Report January 1 – December 31, 2026,	February 11, 2027
Interim report January 1 – March 31, 2027,	April 27, 2027

Reports may be downloaded at the Genovis website:
https://investor.genovis.com/en/financial-reports/ or requested from the company by phone or letter: Genovis AB, Box 4, 244 21 Kävlinge, Sweden. Tel.: 046-10 12 30

Forward-looking information
This report contains forward-looking information based on the current expectations of Group management at Genovis. Although the management believes that the expectations reflected in such forward-looking information are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

Financial information - Group

Statement of comprehensive income

	jul-sep		jan-sep		full year
(SEK 000s)	2026	2025	2026	2025	2025
Net sales	36,872	27,532	104,694	88,694	128,946
Change in inventory, finished goods	-654	-399	-62	345	-120
Work performed by the entity and capitalised	593	206	1,266	700	705
Other operating income	3,131	1,446	9,369	2,552	3,294
	39,942	**28,785**	**115,267**	**92,291**	**132,825**
Raw materials and consumables	-3,516	-2,482	-12,217	-9,691	-13,679
Personnel expense	-14,854	-10,260	-41,403	-32,124	-47,079
Other external expenses	-9,627	-6,344	-25,246	-20,857	-29,007
Other operating expenses	-1,656	-2,821	-9,761	-7,799	-9,502
Operating profit before depreciation and amortization (EBITDA)	**10,289**	**6,878**	**26,640**	**21,820**	**33,558**
Depreciation, amortization and impairment of plant, property, and equipment and intangible assets	-4,513	-3,504	-12,266	-8,599	-12,275
Operating profit (EBIT)	**5,776**	**3,374**	**14,374**	**13,221**	**21,283**
Net financial items	-322	-358	-896	-644	-1,013
The share of profit or loss after tax from associates accounted for using the equity method	0	6,293	0	6,538	6,538
Profit before tax	**5,454**	**9,309**	**13,478**	**19,115**	**26,808**
Income tax	-1,291	-1,283	-3,748	-2,517	-3,310
Profit for the period	**4,163**	**8,026**	**9,730**	**16,598**	**23,498**
Items that may be reclassified subsequently to profit or loss					
Translation of foreign subsidiary	1,775	844	4,851	3,116	4,206
Comprehensive income for the period*	**5,938**	**8,870**	**14,581**	**19,714**	**27,704**

** The entire profit is attributable to Parent Company shareholders*

	jul-sep		jan-sep		full year
	2026	2025	2026	2025	2025
Earnings per share (SEK)*	0.06	0.12	0.15	0.25	0.36
Comprehensive income per share (SEK)*	0.09	0.13	0.22	0.30	0.42
Number of shares					
Weighted average for the period	67,458,379	66,062,792	66,686,461	65,677,037	65,781,830
Number of shares at start of period	67,458,379	65,465,714	66,062,792	65,465,714	65,465,714
Proceeds from new share issue	0	597,078	1,395,587	597,078	597,078
Number of shares at end of period	67,458,379	66,062,792	67,458,379	66,062,792	66,062,792
Share price at end of period, SEK	18.78	23.25	18.78	23.25	21.25

** Based on weighted average of the number of outstanding shares (basic and diluted)*

Condensed Balance Sheet

(SEK 000s)	Sep. 30 2026	Sep. 30 2025	Dec. 31 2025
Assets			
Noncurrent assets			
Intangible assets	131,761	80,449	79,304
Property, plant and equipment	84,487	83,444	83,931
Financial assets	136	131	129
Deferred tax assets	11,202	8,183	7,948
Investments in associates accounted for using the equity method	0	0	0
Current assets			
Current assets	51,907	38,899	43,430
Cash and cash equivalents	163,012	154,888	163,192
Total assets	**442,505**	**365,994**	**377,934**
Equity and liabilities			
Equity	313,938	263,534	271,524
Deferred tax	10,993	5,922	6,061
Noncurrent liabilities	72,387	78,554	72,278
Current liabilities	45,187	17,984	28,071
Total equity and liabilities	**442,505**	**365,994**	**377,934**

Statement of Changes in Equity

(SEK 000s)	Sep. 30 2026	Sep. 30 2025	Dec. 31 2025
Opening balance	271,524	227,972	227,972
Profit for the period	9,730	16,598	23,498
Other comprehensive income for the period	4,851	3,116	4,206
Total comprehensive income for the period	**14,581**	**19,714**	**27,704**
Transactions with owners of the group			
Proceeds from new share issue, net	27,833	15,848	15,848
Sum transactions with owners of the group	**27,833**	**15,848**	**15,848**
Closing balance	**313,938**	**263,534**	**271,524**
Attributable to shareholders in Genovis AB	313,938	263,534	271,524

Key financial indicators	Sep. 30 2026	Sep. 30 2025	Dec. 31 2025
Equity/assets ratio (%)	71	72	72
Equity per share at end of period* (SEK)	4.71	4.01	4.13

** Based on weighted average of the number of outstanding shares (basic and diluted)*

Condensed Statement of Cash Flows

	jul-sep		jan-sep		full year
(SEK 000s)	2026	2025	2026	2025	2025
Operating profit for the period	**5,776**	**3,374**	**14,374**	**13,221**	**21,283**
Adjustment for items not affecting cash flow	4,513	3,504	12,266	8,599	12,275
Changes in working capital	4,613	4,355	13,250	-5,050	-523
Net financial items	-322	-358	-896	-644	-1,013
Cash flow from operating activities	**14,580**	**10,875**	**38,994**	**16,126**	**32,022**
Investing activities	-7,155	-42,139	-60,342	-52,037	-53,497
Cash flow after investing activities	**7,425**	**-31,264**	**-21,348**	**-35,911**	**-21,475**
Financing activities	-1,604	17,163	21,168	21,357	15,225
Cash flow for the period	**5,821**	**-14,101**	**-180**	**-14,554**	**-6,250**
Cash and cash equivalents at start of period	157,191	168,989	163,192	169,442	169,442
Cash and cash equivalents at end of period	**163,012**	**154,888**	**163,012**	**154,888**	**163,192**

Financial information – Parent Company

Condensed Income Statement

	jul-sep		jan-sep		full year
(SEK 000s)	2026	2025	2026	2025	2025
Operating income incl. change in inventory of finished goods and capitalised work performed for own account	29,328	21,126	96,609	79,034	111,877
Operating expenses	-24,174	-18,704	-75,065	-61,913	-87,013
Operating profit	**5,154**	**2,422**	**21,544**	**17,121**	**24,864**
Net financial items	490	532	1,601	2,166	2,667
Profit after financial items	**5,644**	**2,954**	**23,145**	**19,287**	**27,531**
Group contribution paid	0	0	0	0	-16,796
Appropriations	0	0	0	0	-515
Profit before tax	**5,644**	**2,954**	**23,145**	**19,287**	**10,220**
Income tax	-1,137	0	-4,794	-1,814	-2,133
Profit for the period	**4,507**	**2,954**	**18,351**	**17,473**	**8,087**

Condensed Balance Sheet

	Sep. 30	Sep. 30	Dec. 31
(SEK 000s)	2026	2025	2025
Assets			
Noncurrent assets	177,930	117,889	117,487
Deferred tax assets	0	0	0
Current assets	66,785	52,084	44,867
Cash and cash equivalents	124,308	121,425	139,889
Total assets	**369,023**	**291,398**	**302,243**
Equity and liabilities			
Restricted equity	19,308	18,047	18,021
Unrestricted equity	287,551	252,014	242,654
Untaxed reserves	515	0	515
Liabilities			
Noncurrent liabilities	9,865	7,063	5,521
Current liabilities	51,784	14,274	35,532
Total equity and liabilities	**369,023**	**291,398**	**302,243**

Statement of Changes in Equity

	Sep. 30	Sep. 30	Dec. 31
(SEK 000s)	2026	2025	2025
Opening balance	260,675	236,740	236,740
Profit for the period	18,351	17,473	8,087
Proceeds from new share issue, net*	27,833	15,848	15,848
Amount at end of period	**306,859**	**270,061**	**260,675**
Attributable to shareholders in Genovis AB	306,859	270,061	260,675

**Total costs for the new share issue amounted to SEK 218 thousand.*

Condensed Statement of Cash Flows

	jul-sep		jan-sep		full year
(SEK 000s)	2026	2025	2026	2025	2025
Operating profit for the period	**5,154**	**2,422**	**21,544**	**17,121**	**24,864**
Adjustment for items not affecting cash flow	1,194	1,094	3,464	2,936	4,050
Changes in working capital	-5,794	3,129	-10,460	-16,333	-4,973
Net financial items	866	462	2,268	2,095	2,435
Cash flow from operating activities	**1,420**	**7,107**	**16,816**	**5,819**	**26,376**
Investing activities	-7,155	-55,601	-63,907	-65,499	-66,212
Cash flow after investing activities	**-5,735**	**-48,494**	**-47,091**	**-59,680**	**-39,836**
Financing activities	0	15,848	31,510	22,981	21,601
Cash flow for the period	**-5,735**	**-32,646**	**-15,581**	**-36,699**	**-18,235**
Cash and cash equivalents at start of period	130,043	154,071	139,889	158,124	158,124
Cash and cash equivalents at end of period	**124,308**	**121,425**	**124,308**	**121,425**	**139,889**

Statement by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Parent Company's and the Group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

Kävlinge, November 10, 2026
Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson
Chief Executive Officer

For more information

Additional information about the Company is available on its website: www.genovis.com
For questions about this report, please contact: Fredrik Olsson, CEO, and President,
Tel.: +46 (0)702-276 46 56. E: fredrik.olsson@genovis.com

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 10, 2026.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

